From the Guidelines
Parents should not give MiraLAX to a 10-month-old infant without consulting a pediatrician first, as there is no standard recommended dose for this age group and it is not officially approved by the FDA for use in infants under 17 years of age. The management of constipation in infants requires a careful approach, considering the potential risks and benefits of different treatments. According to the available evidence, osmotic laxatives such as polyethylene glycol (MiraLAX) can be effective in increasing the amount of water in the large bowel, but their use in infants should be cautious and guided by a healthcare provider 1. If a doctor determines MiraLAX is appropriate, they typically prescribe a very small dose, often starting at 1/4 to 1/2 teaspoon (1.75-3.5 grams) mixed in 2-4 ounces of liquid once daily. However, the dose must be individually determined by the healthcare provider based on the infant's specific situation.
Some key points to consider when managing constipation in a 10-month-old infant include:
- Trying safer alternatives first, such as dietary changes (increased fluid intake, prune or pear juice), gentle belly massage, or glycerin suppositories specifically made for infants
- Evaluating the infant's constipation to rule out underlying medical conditions before any treatment is started
- Consulting a pediatrician before giving MiraLAX or any other laxative to an infant
- Being aware of the potential risks and benefits of different treatments, including the use of stimulant laxatives, which can cause abdominal cramp and hypokalaemia 1.
It is essential to prioritize the infant's safety and well-being, and to seek medical advice from a qualified healthcare provider before initiating any treatment for constipation.
From the Research
Recommended Dose of MiraLAX for a 10-Month-Old Infant with Constipation
The recommended dose of MiraLAX (polyethylene glycol) for a 10-month-old infant with constipation is not explicitly stated in the provided studies. However, based on the available evidence, the following information can be gathered:
- A study published in 2003 found that the average final dose of polyethylene glycol 3350 for children with dysfunctional elimination was 0.63 gm/kg 2.
- Another study published in 2001 found that the mean effective dose of polyethylene glycol 3350 for children with chronic constipation was 0.84 g/kg/d, with a range of 0.27-1.42 g/kg/d 3.
- A study published in 2002 found that the mean initial treatment dosage of polyethylene glycol without electrolytes for children with constipation and encopresis was 0.6 +/- 0.2 g/kg daily 4.
Key Points to Consider
- The dose of MiraLAX may need to be adjusted based on the individual child's response to treatment.
- The studies suggest that polyethylene glycol 3350 is a safe and effective treatment for constipation in children, but the optimal dose may vary depending on the child's age, weight, and severity of constipation.
- It is essential to consult with a healthcare provider to determine the appropriate dose of MiraLAX for a 10-month-old infant with constipation, as they can assess the child's individual needs and provide personalized guidance.
Important Considerations
- Polyethylene glycol 3350 is generally considered safe and well-tolerated in children, but it may cause side effects such as diarrhea in some cases 2.
- The use of MiraLAX in children under 2 years of age is not well-studied, and therefore, it is crucial to consult with a healthcare provider before administering the medication to a 10-month-old infant 5.